title: Berberine inhibits arylamine N-acetyltransferase activity and gene expression in mouse leukemia L 1210 cells.
abstract: N-acetyltransferases (NATs) are recognized to play a key role in the primary step of arylamine compounds metabolism. Polymorphic NAT is coded for rapid or slow acetylators, which are being thought to involve cancer risk related to environmental exposure. Berberine has been shown to induce apoptosis and affect NAT activity in human leukemia cells. The purpose of this study is to examine whether or not berberine could affect arylamine NAT activity and gene expression (NAT mRNA) and the levels of NAT protein in mouse leukemia cells (L 1210). N-acetylated and non-N-acetylated AF were determined and quantited by using high performance liquid chromatography. NAT mRNA was determined and quantited by using RT-PCR. The levels of NAT protein were examined by western blotting and determined by using flow cytometry. Berberine displayed a dose-dependent inhibition to cytosolic NAT activity and intact mice leukemia cells. Time-course experiments indicated that N-acetylation of AF measured from intact mice leukemia cells were inhibited by berberine for up to 24 h. The NAT1 mRNA and NAT proteins in mouse leukemia cells were also inhibited by berberine. This report is the first demonstration, which showed berberine affect mice leukemia cells NAT activity, gene expression (NAT1 mRNA) and levels of NAT protein.
authors.affiliation: Department of Radiological Technology, Chungtai Institute of Health Sciences and Technology, Taichung, Taiwan, ROC.
authors.forename: S S
authors.initials: SS
authors.lastname: Lin
authors.forename: J G
authors.initials: JG
authors.lastname: Chung
authors.forename: J P
authors.initials: JP
authors.lastname: Lin
authors.forename: J Y
authors.initials: JY
authors.lastname: Chuang
authors.forename: W C
authors.initials: WC
authors.lastname: Chang
authors.forename: J Y
authors.initials: JY
authors.lastname: Wu
authors.forename: Y S
authors.initials: YS
authors.lastname: Tyan
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001191:Arylamine N-Acetyltransferase / Q000187:drug effects*; D001599:Berberine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D028142:Berberis; D015153:Blotting, Western; D045744:Cell Line, Tumor / Q000187:drug effects; D017931:DNA Primers; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D007939:Leukemia L1210 / Q000517:prevention & control; D051379:Mice; D008517:Phytotherapy; D012333:RNA, Messenger / Q000187:drug effects* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017931:DNA Primers; D012333:RNA, Messenger; D001599:Berberine; D001191:Arylamine N-Acetyltransferase